ArticleBMC complementary medicine and therapies2026
Chicoric acid prevents motor dysfunction in zebrafish Parkinson's disease model through Nrf2-mediated antioxidant effect.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zebrafish Models of Parkinson's Disease: From Pathogenesis to Drug Discovery.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChicoric acid (CA) has been used as a nutritional supplement, health food, and medicine because of its antioxidant property. This study aimed to investigate whether CA can prevent motor dysfunction in a zebrafish model of Parkinson's disease (PD).
methodsAB-strain zebrafish (24 hours post-fertilization) were incubated with 25 µM 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) with or without CA for 5 days. The levels of malondialdehyde, glutathione, reactive oxygen species and the activities of antioxidant enzymes in brain tissue were measured. Additionally, the expression of molecules from the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway were assayed by Western blot.
resultsCompared with the control group, zebrafish in the MPTP group had impaired motor function. Treatment with CA prevented the changes of the total distance, the mean speed, and attenuated dopaminergic neuronal degeneration in the PD zebrafish model. CA also reduced the levels of malondialdehyde, reactive oxygen species and increased the antioxidant enzymes and glutathione level. Furthermore, CA augmented the expression of Nrf2, NQO1, HO-1, GCLC, and GCLM in the brain of the PD zebrafish model.
conclusionOur findings suggest the protective effects of CA may be associated with regulating the antioxidant system, possibly involving the Nrf2 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.